Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIDERMAN: Alternating Testosterone and Darolutamide in Metastatic Prostate Cancer
NCT07142551Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2026
- Primary completion
- Jun 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of testosterone cypionate and darolutamide in Metastatic Prostate Cancer (mPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Progression-Free Survival at 24 months. Started Mar 2026; status: recruiting.
02
Drugs
testosterone cypionatedarolutamide
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT07142551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142551.